D. S. Heo

824 total citations
21 papers, 622 citations indexed

About

D. S. Heo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, D. S. Heo has authored 21 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 3 papers in Public Health, Environmental and Occupational Health. Recurrent topics in D. S. Heo's work include Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (4 papers). D. S. Heo is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (4 papers). D. S. Heo collaborates with scholars based in South Korea, Ethiopia and Puerto Rico. D. S. Heo's co-authors include Dongwook Kim, Kim Js, Sun‐Young Kim, Sang Won Shin, Yung‐Jue Bang, Se‐Hoon Lee, Seock‐Ah Im, Bhumsuk Keam, Dong Yoon Oh and S. Im and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Radiotherapy and Oncology.

In The Last Decade

D. S. Heo

19 papers receiving 601 citations

Peers

Countries citing papers authored by D. S. Heo

Since Specialization

Citations

This map shows the geographic impact of D. S. Heo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. S. Heo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. S. Heo more than expected).

Fields of papers citing papers by D. S. Heo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. S. Heo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. S. Heo. The network helps show where D. S. Heo may publish in the future.

Co-authorship network of co-authors of D. S. Heo

This figure shows the co-authorship network connecting the top 25 collaborators of D. S. Heo. A scholar is included among the top collaborators of D. S. Heo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. S. Heo. D. S. Heo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cognitive Impairment Screening Test in Korea as a Screening Tool for Dementia: The Correlation Study of Subtest Scores With Korean Version of the Mini Mental State Examination 2nd Edition 2025 ·Dementia and Neurocognitive Disorders ·(unknown), D. S. Heo, (unknown), (unknown), (unknown), (unknown), Han Jo Kim	0
2	Impact of the Ventricle Size on Alzheimer’s Disease Progression: A Retrospective Longitudinal Study 2024 ·Dementia and Neurocognitive Disorders ·(unknown), D. S. Heo, (unknown), Han Jo Kim	5
3	EP-1149 Albumin-to-alkaline phosphatase ratio in nasopharyngeal cancer: a propensity score matching analysis 2019 ·Radiotherapy and Oncology ·(unknown), Bhumsuk Keam, D. S. Heo, (unknown), Chae‐Seo Rhee, (unknown), (unknown), (unknown)	0
4	A phase II trial of pazopanib in patients with metastatic alveolar soft part sarcoma 2016 ·Annals of Oncology ·(unknown), T. M. Kim, Bhumsuk Keam, Dongwook Kim, D. S. Heo	3
5	Comparison of Treatment Outcomes Between Involved-field and Elective Nodal Irradiation in Limited-stage Small Cell Lung Cancer 2012 ·Japanese Journal of Clinical Oncology ·(unknown), Han Jo Kim, (unknown), D. S. Heo, YW Kim, Se‐Hoon Lee	8
6	Do the preferences of patients with terminal cancer or their family caregivers and end-of-life care discussions influence utilization of hospice-palliative care? 2011 ·Journal of Clinical Oncology ·(unknown), Young Ho Yun, (unknown), Kyung Hae Jung, (unknown), (unknown), D. S. Heo, Jeong Sil Choi, (unknown), Hyun Sik Jeong, (unknown), (unknown), Jungsil Ro, (unknown)	2
7	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). 2010 ·Journal of Clinical Oncology ·(unknown), (unknown), D. S. Heo, Sokbom Kang, (unknown), Daesu Lee, (unknown), (unknown), Ji-Ho Choi, (unknown)	9
8	A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced solid tumors. 2010 ·Journal of Clinical Oncology ·(unknown), Shuwen Han, (unknown), (unknown), (unknown), D. S. Heo, (unknown)	8
9	PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study. 2010 ·Journal of Clinical Oncology ·(unknown), D. S. Heo, (unknown), (unknown), (unknown), (unknown), Robert Millham, Alicyn Campbell, (unknown), (unknown)	20
10	Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma 2009 ·Annals of Oncology ·(unknown), Yoon Kyung Jeon, T. M. Kim, Jeong Eun Kim, (unknown), Seung Hoo Lee, Dong Wook Kim, D. S. Heo, (unknown)	41
11	A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN): Interim analysis 2009 ·Journal of Clinical Oncology ·K. Park, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Gangcai Zhu, D. S. Heo, Yichen Wu	3
12	A multicenter phase II study to evaluate efficacy and safety of gefitinib as the first-line treatment for Korean patients (pts) with advanced pulmonary adenocarcinoma harboring EGFR mutations 2009 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), Jin‐Hyoung Kang, (unknown), Seong Hoon Shin, (unknown), D. S. Heo	1
13	Aggressiveness of Cancer-Care near the End-of-Life in Korea 2008 ·Japanese Journal of Clinical Oncology ·Bhumsuk Keam, Djin‐Ye Oh, Se‐Hoon Lee, Dongwook Kim, Mee‐Ran Kim, S. Im, Tae‐Yop Kim, Yung‐Jue Bang, D. S. Heo	85
14	Response to erlotinib after failure of gefitinib in non-small cell lung cancer with EGFR mutation 2008 ·Journal of Clinical Oncology ·(unknown), (unknown), Soo Jin Oh, Min Ji Seo, (unknown), (unknown), D. S. Heo	3
15	Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma 2007 ·Annals of Oncology ·Eun‐Kee Song, (unknown), (unknown), (unknown), Tak Yun, (unknown), (unknown), (unknown), Dongwook Kim, Sang In Khwarg, D. S. Heo	46
16	A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer 2007 ·Annals of Oncology ·Young Jae Kim, Seock‐Ah Im, (unknown), Sung Yong Oh, Kyung-Woo Lee, In Sil Choi, Do‐Youn Oh, Sang Hoon Lee, Jin Hyoung Kim, (unknown), Taewoo Kim, Seung Woo Kim, D. S. Heo, Yong Bum Yoon, Yung‐Jue Bang	43
17	Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer 2007 ·Annals of Oncology ·Dongwook Kim, Sun‐Young Kim, (unknown), (unknown), Sang Won Shin, Kim Js, (unknown), (unknown), D. S. Heo	256
18	Antibiotic use during the last days of life in cancer patients 2006 ·European Journal of Cancer Care ·Dong Yoon Oh, (unknown), Dong‐Wan Kim, Seock‐Ah Im, (unknown), D. S. Heo, Y-J. Bang, (unknown)	62
19	Efficacy of reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer (CRC) 2005 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), In‐Suk Choi, (unknown), (unknown), (unknown), (unknown), D. S. Heo, Yu Jeong Bang, (unknown)	5
20	Single-agent Capecitabine in Patients with Metastatic Colorectal Cancer Refractory to 5-Fluorouracil/Leucovorin Chemotherapy 2004 ·Japanese Journal of Clinical Oncology ·Jeonghee Lee, T. M. Kim, Su Jong Yu, Dongwook Kim, (unknown), Dong Yoon Oh, Jung Hye Kwon, Taewoo Kim, D. S. Heo, Yu Jeong Bang, Namkug Kim	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact